![](/images/graphics-bg.png)
Sequential Kinase Inhibition (IdelalisibIbrutinib) Induces Clinical Remission in B-Cell Prolymphocytic Leukemia Harboring a 17p Deletion
Joint Authors
Source
Issue
Vol. 2017, Issue 2017 (31 Dec. 2017), pp.1-4, 4 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2017-07-27
Country of Publication
Egypt
No. of Pages
4
Main Subjects
Abstract EN
B-cell prolymphocytic leukemia (B-PLL) is a rare lymphoid neoplasm with an aggressive clinical course.
Treatment strategies for B-PLL remain to be established, and, until recently, alemtuzumab was the only effective therapeutic option in patients harboring 17p deletions.
Herein, we describe, for the first time, a case of B-cell prolymphocytic leukemia harboring a 17p deletion in a 48-year-old man that was successfully treated sequentially with idelalisib-rituximab/ibrutinib followed by allogeneic hematopoietic stem cell transplant (allo-HSCT).
After 5 months of therapy with idelalisib-rituximab, clinical remission was achieved, but the development of severe diarrhea led to its discontinuation.
Subsequently, the patient was treated for 2 months with ibrutinib and the quality of the response was maintained with no severe adverse effects reported.
A reduced-intensity conditioning allo-HSCT from a HLA-matched unrelated donor was performed, and, thereafter, the patient has been in complete remission for 10 months now.
In conclusion, given the poor prognosis of B-PLL and the lack of effective treatment modalities, the findings here suggest that both ibrutinib and idelalisib should be considered as upfront therapy of B-PLL and as a bridge to allo-HSCT.
American Psychological Association (APA)
Coelho, H.& Badior, M.& Melo, T.. 2017. Sequential Kinase Inhibition (IdelalisibIbrutinib) Induces Clinical Remission in B-Cell Prolymphocytic Leukemia Harboring a 17p Deletion. Case Reports in Hematology،Vol. 2017, no. 2017, pp.1-4.
https://search.emarefa.net/detail/BIM-1146044
Modern Language Association (MLA)
Coelho, H.…[et al.]. Sequential Kinase Inhibition (IdelalisibIbrutinib) Induces Clinical Remission in B-Cell Prolymphocytic Leukemia Harboring a 17p Deletion. Case Reports in Hematology No. 2017 (2017), pp.1-4.
https://search.emarefa.net/detail/BIM-1146044
American Medical Association (AMA)
Coelho, H.& Badior, M.& Melo, T.. Sequential Kinase Inhibition (IdelalisibIbrutinib) Induces Clinical Remission in B-Cell Prolymphocytic Leukemia Harboring a 17p Deletion. Case Reports in Hematology. 2017. Vol. 2017, no. 2017, pp.1-4.
https://search.emarefa.net/detail/BIM-1146044
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1146044